Skip to main content
Erschienen in: Endocrine 3/2020

31.03.2020 | Original Article

The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study

verfasst von: Bruno Madeo, Sara De Vincentis, Andrea Repaci, Paola Altieri, Valentina Vicennati, Elda Kara, Fabio Vescini, Pierluigi Amadori, Antonio Balestrieri, Uberto Pagotto, Manuela Simoni, Vincenzo Rochira

Erschienen in: Endocrine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The diagnosis of primary hyperparathyroidism (PHPT) and chronic hypoparathyroidism (HypoPT) is still challenging, especially in patients asymptomatic or with non-classical phenotypes and for physicians not skilled in calcium-phosphorous (Ca–P) disorders. The serum calcium/phosphorous (Ca/P) ratio has been proposed as accurate index to identify PHPT, while it has never been tested in HypoPT. The aim of this study is to investigate the diagnostic power of the serum Ca/P ratio in the diagnosis of primary parathyroid dysfunctions (both PHPT and HypoPT) in a large series of data.

Methods

A multicentric, retrospective, cross-sectional study (ClinicalTrials.gov: NCT03747029) was carried out including 432 PHPT patients and 217 HypoPT patients compared with 389 controls. Serum Ca, P, creatinine, parathyroid hormone and 25OH-vitamin D were collected. Serum Ca and P were expressed in mmol/L. Ca/P diagnostic performance was evaluated by receiver operating characteristic (ROC) curve, sensitivity, specificity and accuracy.

Results

The Ca/P ratio was significantly higher in PHPT and lower in HypoPT patients than controls (p < 0.0001). At ROC curve analysis, the Ca/P ratio above 2.55 was defined to identify PHPT patients (sensitivity 85.7%, specificity 85.3%) and below 1.78 to identify HypoPT patients (sensitivity 88.2%, specificity 87.9%).

Conclusions

The Ca/P ratio is a highly accurate index to identify PHPT when Ca/P is above 2.55 and HypoPT when it is below 1.78. These results demonstrate the reliability of this index to rule in/out primary parathyroid dysfunctions and remark the importance of measuring serum P in clinical practice.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat J.L. Shaker, L. Deftos. Calcium and Phosphate Homeostasis. [Updated 2018 Jan 19]. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 J.L. Shaker, L. Deftos. Calcium and Phosphate Homeostasis. [Updated 2018 Jan 19]. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000
2.
Zurück zum Zitat M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115–125 (2018)CrossRef M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115–125 (2018)CrossRef
3.
Zurück zum Zitat S. Minisola, L. Gianotti, S. Bhadada, S.J. Silverberg, Classical complications of primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 791–803 (2018)CrossRef S. Minisola, L. Gianotti, S. Bhadada, S.J. Silverberg, Classical complications of primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 791–803 (2018)CrossRef
4.
Zurück zum Zitat M. Peacock, Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol. 5(Suppl 1), S23–S30 (2010)CrossRef M. Peacock, Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol. 5(Suppl 1), S23–S30 (2010)CrossRef
5.
Zurück zum Zitat B. Madeo, S. De Vincentis, E. Kara, F. Vescini, T. Trenti, et al. Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool inthe diagnosis of some Ca-P disorders. J. Endocrinol. Investig. 42, 1041–1049 (2019) B. Madeo, S. De Vincentis, E. Kara, F. Vescini, T. Trenti, et al. Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool inthe diagnosis of some Ca-P disorders. J. Endocrinol. Investig. 42, 1041–1049 (2019)
6.
Zurück zum Zitat M. Mannstadt, J.P. Bilezikian, R.V. Thakker, F.M. Hannan, B.L. Clarke et al. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017)CrossRef M. Mannstadt, J.P. Bilezikian, R.V. Thakker, F.M. Hannan, B.L. Clarke et al. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017)CrossRef
7.
Zurück zum Zitat B. Madeo, E. Kara, K. Cioni, S. Vezzani, T. Trenti et al. Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR 2, 109–117 (2018) B. Madeo, E. Kara, K. Cioni, S. Vezzani, T. Trenti et al. Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR 2, 109–117 (2018)
8.
Zurück zum Zitat J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet 391, 168–178 (2018)CrossRef J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet 391, 168–178 (2018)CrossRef
9.
Zurück zum Zitat S.J. Silverberg, J.P. Bilezikian, “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J. Clin. Endocrinol. Metab. 88, 5348–5352 (2003)CrossRef S.J. Silverberg, J.P. Bilezikian, “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J. Clin. Endocrinol. Metab. 88, 5348–5352 (2003)CrossRef
10.
Zurück zum Zitat A.N. Hollenberg, A. Arnold, Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am. J. Med. 91, 547–548 (1991)CrossRef A.N. Hollenberg, A. Arnold, Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am. J. Med. 91, 547–548 (1991)CrossRef
11.
Zurück zum Zitat S. Corbetta, Normocalcemic hyperparathyroidism. Front. Horm. Res. 51, 23–39 (2019)CrossRef S. Corbetta, Normocalcemic hyperparathyroidism. Front. Horm. Res. 51, 23–39 (2019)CrossRef
12.
13.
Zurück zum Zitat C. Marcocci, F. Cetani, Clinical practice. Primary hyperparathyroidism. N. Engl. J. Med. 365, 2389–2397 (2011)CrossRef C. Marcocci, F. Cetani, Clinical practice. Primary hyperparathyroidism. N. Engl. J. Med. 365, 2389–2397 (2011)CrossRef
14.
Zurück zum Zitat J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014)CrossRef J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014)CrossRef
15.
Zurück zum Zitat M.M. Tuna, M. Caliskan, M. Unal, T. Demirci, B.A. Dogan et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Min. Metab. 34, 331–335 (2016)CrossRef M.M. Tuna, M. Caliskan, M. Unal, T. Demirci, B.A. Dogan et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Min. Metab. 34, 331–335 (2016)CrossRef
16.
Zurück zum Zitat D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391–403 (2008)CrossRef D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391–403 (2008)CrossRef
17.
Zurück zum Zitat M.L. Brandi, J.P. Bilezikian, D. Shoback, R. Bouillon, B.L. Clarke et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273–2283 (2016)CrossRef M.L. Brandi, J.P. Bilezikian, D. Shoback, R. Bouillon, B.L. Clarke et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273–2283 (2016)CrossRef
18.
Zurück zum Zitat J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173, G1–G20 (2015)CrossRef J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173, G1–G20 (2015)CrossRef
19.
Zurück zum Zitat D.M. Shoback, J.P. Bilezikian, A.G. Costa, D. Dempster, H. Dralle et al. Presentation of hypoparathyroidism: etiologies and clinical features. J. Clin. Endocrinol. Metab. 101, 2300–2312 (2016)CrossRef D.M. Shoback, J.P. Bilezikian, A.G. Costa, D. Dempster, H. Dralle et al. Presentation of hypoparathyroidism: etiologies and clinical features. J. Clin. Endocrinol. Metab. 101, 2300–2312 (2016)CrossRef
20.
Zurück zum Zitat N.E. Cusano, J.P. Bilezikian, Signs and symptoms of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 759–770 (2018)CrossRef N.E. Cusano, J.P. Bilezikian, Signs and symptoms of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 759–770 (2018)CrossRef
21.
Zurück zum Zitat L. Cianferotti, G. Marcucci, M.L. Brandi, Causes and pathophysiology of hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 909–925 (2018)CrossRef L. Cianferotti, G. Marcucci, M.L. Brandi, Causes and pathophysiology of hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 909–925 (2018)CrossRef
22.
Zurück zum Zitat E.A. Alore, J.W. Suliburk, D.J. Ramsey, N.N. Massarweh, C.J. Balentine, et al. Diagnosis and Management of Primary Hyperparathyroidism Across theVeterans Affairs Health Care System. JAMA Intern Med. 179, 1220–1227 (2019) E.A. Alore, J.W. Suliburk, D.J. Ramsey, N.N. Massarweh, C.J. Balentine, et al. Diagnosis and Management of Primary Hyperparathyroidism Across theVeterans Affairs Health Care System. JAMA Intern Med. 179, 1220–1227 (2019)
23.
Zurück zum Zitat J. Bollerslev, C. Schalin-Jantti, L. Rejnmark, H. Siggelkow, H. Morreau et al. Management of endocrine disease: unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 181, P1–p19 (2019)CrossRef J. Bollerslev, C. Schalin-Jantti, L. Rejnmark, H. Siggelkow, H. Morreau et al. Management of endocrine disease: unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 181, P1–p19 (2019)CrossRef
24.
Zurück zum Zitat M. Pawlowska, N.E. Cusano, An overview of normocalcemic primary hyperparathyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 22, 413–421 (2015)CrossRef M. Pawlowska, N.E. Cusano, An overview of normocalcemic primary hyperparathyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 22, 413–421 (2015)CrossRef
25.
Zurück zum Zitat N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 837–845 (2018)CrossRef N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 837–845 (2018)CrossRef
26.
Zurück zum Zitat H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007)CrossRef H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007)CrossRef
27.
Zurück zum Zitat L. Underbjerg, T. Sikjaer, L. Rejnmark, Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J. Bone Min. Res. 33, 822–831 (2018)CrossRef L. Underbjerg, T. Sikjaer, L. Rejnmark, Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J. Bone Min. Res. 33, 822–831 (2018)CrossRef
28.
Zurück zum Zitat M.C. Astor, K. Lovas, A. Debowska, E.F. Eriksen, J.A. Evang et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J. Clin. Endocrinol. Metab. 101, 3045–3053 (2016)CrossRef M.C. Astor, K. Lovas, A. Debowska, E.F. Eriksen, J.A. Evang et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J. Clin. Endocrinol. Metab. 101, 3045–3053 (2016)CrossRef
29.
Zurück zum Zitat M.R. Rubin, Skeletal manifestations of hypoparathyroidism. Bone 120, 548–555 (2019)CrossRef M.R. Rubin, Skeletal manifestations of hypoparathyroidism. Bone 120, 548–555 (2019)CrossRef
30.
Zurück zum Zitat B.L. Clarke, Epidemiology and complications of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 771–782 (2018)CrossRef B.L. Clarke, Epidemiology and complications of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 771–782 (2018)CrossRef
31.
Zurück zum Zitat I.H. de Boer, T.C. Rue, B. Kestenbaum, Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 53, 399–407 (2009)CrossRef I.H. de Boer, T.C. Rue, B. Kestenbaum, Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 53, 399–407 (2009)CrossRef
32.
Zurück zum Zitat W.C. O’Neill, The fallacy of the calcium-phosphorus product. Kidney Int. 72, 792–796 (2007)CrossRef W.C. O’Neill, The fallacy of the calcium-phosphorus product. Kidney Int. 72, 792–796 (2007)CrossRef
Metadaten
Titel
The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study
verfasst von
Bruno Madeo
Sara De Vincentis
Andrea Repaci
Paola Altieri
Valentina Vicennati
Elda Kara
Fabio Vescini
Pierluigi Amadori
Antonio Balestrieri
Uberto Pagotto
Manuela Simoni
Vincenzo Rochira
Publikationsdatum
31.03.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02276-7

Weitere Artikel der Ausgabe 3/2020

Endocrine 3/2020 Zur Ausgabe

Endocrine imaging

Pemberton sign

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.